The world of COVID-19 variants has been relatively quiet lately, but a new name is buzzing in the headlines: Cicada (BA.3.2). Just like the insect it’s named after, this variant seemed to emerge from a long period of dormancy to suddenly spike in genomic sequencing reports across the globe. But is it a cause for alarm, or just another evolutionary ripple?
In this deep dive, we explore the origins, symptoms, and the actual risk level of the Cicada variant to keep you informed and prepared.
What is the Cicada (BA.3.2) Variant?
The Cicada variant is a sub-lineage of the Omicron family. While it was technically first detected in late 2024 in South Africa, it failed to gain momentum for months. However, recent data from early 2026 shows a significant uptick in cases across Europe and North America.
Scientists nicknamed it "Cicada" because of its "stop-and-start" nature—staying underground for a long period before resurfacing with a flurry of new mutations.
The Science: Why Mutations Matter
BA.3.2 carries over 70 mutations, many of which are located on the spike protein. This is the part of the virus that attaches to human cells. The high number of mutations suggests two things:
- Increased Transmissibility: It may spread more easily in households than previous sub-variants.
- Immune Evasion: It has shown a knack for "hiding" from antibodies generated by older vaccines or previous infections.
Current Symptoms to Watch For
While the core symptoms remain similar to classic Omicron, healthcare providers are noting a specific pattern with Cicada:
- Severe Sore Throat: Often described as "glassy" or extremely scratchy.
- Persistent Dry Cough: A lingering cough that lasts longer than the fever.
- Fatigue & Muscle Aches: Significant exhaustion even in mild cases.
- Congestion: Heavy sinus pressure and runny nose.
Should You Be Worried?
The short answer is no, but you should stay vigilant. Public health data indicates that while Cicada is better at infecting people, it is not necessarily better at making them severely ill. Hospitalization rates remain stable, and current antiviral treatments and updated boosters still provide a high level of protection against severe outcomes.